|
Apr 10
|
NRXBF Enters Crucial Stage in Good Shape
|
|
Apr 9
|
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
|
|
Apr 4
|
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
|
|
Feb 14
|
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
|
|
Jul 29
|
NurExone Announces Further Expansion of ExoPTEN Patent Coverage
|
|
Jun 21
|
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
|
|
Mar 27
|
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
|
|
Nov 29
|
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
|
|
Aug 9
|
NurExone Announces Private Placement
|